Stocks · News reference
BofA Securities analyst Jason Gerberry maintained a 'Buy' rating on Eli Lilly and Company while increasing the price target from $1,497 to $1,557.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Zenith Epigenetics has executed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to study the combination of ZEN-3694 and Verzenio in patients with NUT carcinoma.
LifeMD has entered into an arrangement with Eli Lilly and Company to enable the direct dispensing and shipping of Lilly's self-pay GLP-1 medications, including Zepbound and Foundayo, to eligible patients.
Eli Lilly and Company announced it will showcase new clinical and real-world research regarding the use of retatrutide, Taltz, and Zepbound in patients with rheumatologic conditions and obesity.
T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.
The article argues that a 20% decline in the S&P 500 would present a buying opportunity rather than a reason to panic. The author recommends the Vanguard S&P 500 ETF (VOO) as a long-term investment vehicle, citing the S&P 500's 98-year track record of 9.98% annualized returns despite multiple economic crises. The piece emphasizes that while individual stocks can fail, the broader market has consistently recovered and rewarded patient investors.
Following a challenge by Eli Lilly and Company, the National Advertising Division recommended that Good Life Meds, LLC discontinue unsupported health benefit and personalization claims for its compounded tirzepatide products.